Trial in Progress: A Phase II Window of Opportunity Study of the BCMAxCD3 Bispecific Antibody REGN5458 in Previously Untreated Patients with Symptomatic Multiple Myeloma

被引：2

作者：

Ferreri, Christopher J. ^{[1
]}

Quatela, Steven E. ^{[2
]}

Aina, Sean ^{[2
]}

Roy, Pourab ^{[2
]}

Boyapati, Anita ^{[2
]}

Lorenc, Karen Rodriguez ^{[2
]}

Kroog, Glenn S. ^{[2
]}

Orlowski, Robert Z. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158396

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：10129 / 10130

页数：2

共 50 条

[31] First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) [J].

Quach, Hang ;

Augustson, Bradley ;

Sia, Hanlon ;

Shah, Nishi ;

Lichtman, Eben, I ;

Liedtke, Michaela ;

Martinet, Camille ;

Menon, Vinu ;

Garton, Andrew ;

Pihlgren, Maria ;

Holkova, Beata ;

Konto, Cyril ;

Pacaud, Lida ;

Khot, Amit .

BLOOD, 2024, 144 :1027-1027

[32] Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy [J].

Bannerji, Rajat ;

Brown, Jennifer R. ;

Advani, Ranjana H. ;

Arnason, Jon ;

O'Brien, Susan M. ;

Allan, John N. ;

Chavez, Julio C. ;

Barnes, Jeffrey A. ;

Joyce, Robin ;

Ansell, Stephen ;

Topp, Max S. ;

Adriaens, Lieve ;

Ufkin, Melanie ;

Kostic, Ana ;

Paccaly, Anne ;

Gao, Bo ;

Trail, Pamela A. ;

Lowy, Israel ;

Brownstein, Carrie .

BLOOD, 2016, 128 (22)

[33] Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study [J].

Horvath, Noemi ;

Spencer, Andrew ;

Kenealy, Melita ;

Joshua, Douglas ;

Campbell, Philip J. ;

Lee, Je-Jung ;

Hou, Jian ;

Qiu, Lugui ;

Kalff, Anna ;

Khong, Tiffany ;

Londhe, Anil ;

Siggins, Sarah ;

van Kooten Losio, Maximiliano ;

Eisbacher, Michael ;

Prince, H. Miles .

LEUKEMIA & LYMPHOMA, 2019, 60 (09) :2122-2133

[34] Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer: trial in progress [J].

Cercek, Andrea ;

Bachet, Jean-Baptiste ;

Capdevilla, Jaume ;

Starling, Naureen ;

Chen, Eric ;

Di Bartolomeo, Maria ;

Yoshino, Takayuki ;

Vlahovic, Gordana ;

Zografos, Eleftherios ;

O'donnell, Sean ;

Szijgyarto, Zsolt ;

Heinemann, Volker .

ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 :59-59

[35] Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a novel BCMAxCD38xCD3 trispecific antibody from the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma patients Free [J].

Garton, Andrew ;

Menon, Vinu ;

Quach, Hang ;

Khot, Amit ;

Augustson, Brad ;

Sia, Hanlon ;

Levitz, David ;

Lichtman, Eben ;

Liedtke, Michaela ;

Martinet, Camille ;

Holkova, Beata ;

Pacaud, Lida ;

Sunitha, G. N. ;

Pihlgren, Maria ;

Perro, Mario ;

Konto, Cyril .

CANCER RESEARCH, 2025, 85 (08)

[36] Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN) [J].

Kastritis, Eftathios ;

Minnema, Monique C. ;

Dimopoulos, Meletios A. ;

Merlini, Giampaolo ;

Sonneveld, Pieter ;

Palladini, Giovanni .

BLOOD, 2019, 134

[37] Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study [J].

An, Gang ;

Huang, Zhongxia ;

Liang, Aibin ;

Fang, Baijun ;

Jing, Hongmei ;

Qiu, Lu-Gui .

BLOOD, 2024, 144 :3377-3377

[38] Efficacy and Safety of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Japanese Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 Monumental-1 Study [J].

Ito, Shigeki ;

Kuroda, Yoshiaki ;

Sunami, Kazutaka ;

Matsue, Kosei ;

Imada, Kazunori ;

Tamura, Hideto ;

Takamoto, Mikihiro ;

Yamazaki, Hiroshi ;

Fujikawa, Ei ;

Pei, Lixia ;

Masterson, Tara J. ;

Campagna, Michela ;

Lau, Bonnie W. ;

Takamatsu, Yasushi .

BLOOD, 2024, 144 :7011-7012

[39] Higher Cumulative Bortezomib Dose Results In Better Overall Survival (OS) In Patients With Previously Untreated Multiple Myeloma (MM) Receiving Bortezomib-Melphalan-Prednisone (VMP) In The Phase 3 VISTA Study [J].

Mateos, Maria-Victoria ;

Richardson, Paul G. ;

Shi, Hongliang ;

Niculescu, Liviu ;

Elliott, Jennifer ;

Dow, Edward ;

van de Velde, Helgi ;

San Miguel, Jesus F. .

BLOOD, 2013, 122 (21)

[40] Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress) [J].

Powles, T. ;

Grande, E. ;

Van Der Heijden, M. ;

Necchi, A. ;

Iyer, G. ;

Drakaki, A. ;

Loriot, Y. ;

Sokolowski, K. ;

Zhang, W. ;

Galsky, M. .

EUROPEAN UROLOGY, 2024, 85 :S1721-S1721

← 1 2 3 4 5 →